Viktor Grünwald, Daniel Keizman, Jens Bedke, Michael D. Staehler, Vsevolod B Matveev, Saby George, Thomas E. Hutson, Ulka N. Vaishampayan, Jaime R. Merchan, Masatoshi Eto, Sun Young Rha, Tom Waddell, Roberto Sabbatini, Philippe Barthélémy, Joseph E. Burgents, Min Ren, Ian Brown, Hakim Saal, Toni K. Choueiri, Robert J. Motzer. "Analyses on impact of tumor burden at progression and changes in IMDC from baseline in patients (pts) with advanced renal cell carcinoma (aRCC) treated with lenvatinib + pembrolizumab (L+P) in the phase 3 CLEAR trial.." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.5_suppl.531